Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer’s Disease Therapy
Pharmaceutics · 03.03.2023 · 15 (3) · 829
DOI: 10.3390/pharmaceutics15030829 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 03.03.2023. Verfasst von Dilyana Georgieva und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, Medical University of Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bulgarian National Science Fund, European Union—NextGenerationEU.
Themen: Demenz
Abstract (Originalsprache)
Natural alkaloid galantamine is widely used for the treatment of mild to moderate Alzheimer’s dementia. Galantamine hydrobromide (GH) is available as fast-release tablets, extended-release capsules, and oral solutions. However, its oral delivery can cause some unwanted side effects, such as gastrointestinal disturbances, nausea, and vomiting. Intranasal administration is one possible way to avoid such unwanted effects. In this work, chitosan-based nanoparticles (NPs) were studied as potential GH delivery vehicles for nasal application. The NPs were synthesized via ionic gelation and studied using dynamic light scattering (DLS) as well as by spectroscopic and thermal methods. The GH-loaded chitosan–alginate complex particles were also prepared as a way to modify the release of GH. The high loading efficiency of the GH was confirmed for both types of particles, at 67% for the GH-loaded chitosan NPs and 70% for the complex chitosan/alginate GH-loaded particles. The mean particle size of the GH-loaded chitosan NPs was about 240 nm, while the sodium alginate coated chitosan particles loaded with GH were expectedly bigger, with a mean particle size of ~286 nm. GH release profiles in PBS at 37 °C were obtained for both types of NPs, and it was found that the GH-loaded chitosan NPs allowed the prolonged release of the incorporated drug for a period of 8 h, while the complex GH-loaded chitosan/alginate NPs released the incorporated GH faster. The stability of the prepared GH-loaded NPs was also demonstrated after 1 year of storage at 5 °C ± 3 °C.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, Medical University of Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria.
- Laboratory on Structure and Properties of Polymers, Faculty of Chemistry and Pharmacy, University of Sofia, 1 James Bourchier Blvd., 1164 Sofia, Bulgaria.
ORCID-Profile: Dilyana Georgieva, Elena Vassileva
Förderung
- Bulgarian National Science Fund
- European Union—NextGenerationEU
Zitieren
APA
Georgieva, D., Nikolova, D., Vassileva, E., & Kostova, B. (2023). Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer’s Disease Therapy. Pharmaceutics, 15(3), 829. https://doi.org/10.3390/pharmaceutics15030829
Vancouver
Georgieva D, Nikolova D, Vassileva E, Kostova B. Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer’s Disease Therapy. Pharmaceutics. 2023;15(3):829. doi:10.3390/pharmaceutics15030829
BibTeX
@article{Georgieva2023,
author = {Georgieva, Dilyana and Nikolova, Denitsa and Vassileva, Elena and Kostova, Bistra},
title = {Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer’s Disease Therapy},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {3},
pages = {829},
doi = {10.3390/pharmaceutics15030829}
}
EUVIMED